Adipocyte Energy Pathway Modulation via ARID5B Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome-wide association studies (GWAS) fail to identify causal genetic variants for complex traits like obesity, particularly non-coding variants, due to incomplete regulatory annotations and uncertainty about relevant cell types and upstream regulators, making it challenging to understand the mechanistic basis of obesity and associated disorders.
Innovation Solution
The method involves modulating energy consumption pathways in adipocytes by targeting the FTO obesity-associated locus, specifically the T-to-C single-nucleotide variant rs1421085, which disrupts the ARID5B repressor motif, leading to increased expression of IRX3 and IRX5, causing a shift from beige/brite to white adipocyte expression programs, thereby affecting lipid accumulation and thermogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genome-wide association studies are conducted to identify obesity-related genetic variants, then statistical associations can be found, but the causal mechanisms remain unknown due to incomplete regulatory annotations and uncertainty about relevant cell types
Solution Approach 1:
The patent uses adipocyte progenitor cells as an intermediary system to study the causal mechanisms of obesity. By differentiating these progenitor cells into mature adipocytes and analyzing gene expression patterns, the researchers can identify how genetic variants like rs1421085 affect lipid metabolism and energy consumption pathways, thereby bridging the gap between statistical associations and causal mechanisms
Solution Approach 2:
The patent employs parameter changes by measuring multiple gene expression parameters (e.g., IRX3, IRX5, UCP1, PGC1A) under different experimental conditions (control vs. genetic variant carriers). This allows the identification of causal relationships by observing how specific genetic variants alter expression patterns of key metabolic genes,ไป่ resolving the uncertainty about causal mechanisms
2Loss of information
If the FTO locus variant rs1421085 is targeted to understand obesity mechanisms, then the regulatory circuitry can be elucidated, but the complexity of multiple downstream targets and pathways increases
Solution Approach 1:
The patent segments the complex regulatory circuitry into distinct functional modules: the FTO locus variant rs1421085 as the upstream regulator, the ARID5B transcription factor as an intermediary, and the downstream target genes (IRX3, IRX5, UCP1, PGC1A) as effectors. This segmentation allows systematic analysis of each component's role while maintaining understanding of the overall pathway, thereby reducing the perceived complexity
3Reliability
If agents are used to modulate energy consumption pathways in adipocytes, then therapeutic effects for obesity can be achieved, but the specificity of targeting particular pathways without affecting other metabolic processes becomes challenging
Solution Approach 1:
The patent utilizes feedback mechanisms by measuring changes in multiple metabolic parameters (gene expression, lipid accumulation, energy consumption) after treating adipocytes with modulating agents. This feedback information allows optimization of treatment strategies to achieve desired therapeutic effects while monitoring for off-target effects, thereby improving both reliability and specificity
Data Source
AI summary
Provided herein is a pathway for adipocyte energy consumption regulation involving ARID5B, genetic variant rs1421085, IRX3, and IRX5. Compositions and methods for modulating the pathway in vitro and in vivo for anti-cachectic and anti-obesity effects are provided. Methods of identifying subjects at risk of developing a disorder mediated by a dysregulation of the energy consumption pathway are also provided.